Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.70 |
| ▸ | CNR2 | P34972 | 16/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626666 | 0.87 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL3482043 | 0.86 | CNR1 (0.67) | CNR1CNR2ADORA2AADORA1 | |
| SCHEMBL19835709 | 0.85 | CNR1 (0.55) | CNR1CNR2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3628024 | 0.83 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL3626102 | 0.83 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL4412951 | 0.81 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL5360588 | 0.80 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL13498508 | 0.79 | NPSR1 (0.69) | CNR1CNR2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5359447 | 0.79 | CNR1 (0.70) | CNR1CNR2 | |
| SCHEMBL3661291 | 0.78 | NPSR1 (0.46) | CNR1CNR2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | claimed |
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | claimed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-7728141-B2 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| EP-2139332-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1682550-B1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO INC (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008121257-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271266-B2 | Substituted 2,3-diphenyl pyridines | MERCK & CO., INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | MERCK SHARP & DOHME CORP. | 2007-02-08 | — | — | US | disclosed |
| EP-1682550-A4 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1682550-A1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | Merck & Co., Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| WO-2005047285-A1 | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182103-A1 | Substituted 2,3-diphenyl pyridines | CNR1, CNR2, MAG | CNR1 1/4885CNR2 2/4885CYP1A2 641/4885 |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP1A2 745/4885 |
| US-20100063032-A1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP1A2 584/4885 |
| US-20070032517-A1 | Substituted naphthyridinone derivatives | CNR1, CNR2, MAG | CNR1 1/4885CNR2 2/4885CYP1A2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.